Mucroporin, the first cationic host defense peptide from the venom of Lychas mucronatus

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 3967-3972

  Dai, Chao ^a   Ma, Yibao ^a   Zhao, Zhenhuan ^a   Zhao, Ruiming ^a   Wang, Qian ^a   Wu, Yingliang ^a   Cao, Zhijian ^a   Li, Wenxin ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CATIONIC HOST DEFENSE PEPTIDE; MUCROPORIN; MUCROPORIN M1; PEPTIDE; SCORPION VENOM; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG MECHANISM; GRAM NEGATIVE BACTERIUM; HOST RESISTANCE; LYCHAS MUCRONATUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SCORPION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BASE SEQUENCE; CLONING, MOLECULAR; DNA PRIMERS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR SEQUENCE DATA; SCORPION VENOMS; SCORPIONS; SEQUENCE HOMOLOGY, AMINO ACID; STAPHYLOCOCCUS AUREUS;

EID: 55849152810     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00542-08     Document Type: Article

References (53)

1. Andres, E., and J. L. Dimarcq. 2004. Cationic antimicrobial peptides: update of clinical development. J. Intern. Med. 255:519-520.
2. Appelbaum, P. C. 2006. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12(Suppl. 1):16-23.
3. Appelbaum, P. C. 2006. MRSA-the tip of the iceberg. Clin. Microbiol. Infect. 12(Suppl. 2):3-10.
4. Avery, R., M. Kalaycio, B. Pohlman, R. Sobecks, E. Kuczkowski, S. Andresen, S. Mossad, J. Shamp, J. Curtis, J. Kosar, K. Sands, M. Serafin, and B. Bolwell. 2005. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant. 35:497-499.
5. + current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res. 58:815-822.
6. Boman, H. G. 1995. Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol. 13:61-92.
7. Bradshaw, J. 2003. Cationic antimicrobial peptides: issues for potential clinical use. Bio Drugs 17:233-240.
8. Brogden, K. A. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250.
9. Brogden, K. A., M. Ackermann, P. B. McCray, Jr., and B. F. Tack. 2003. Antimicrobial peptides in animals and their role in host defenses. Int. J. Antimicrob. Agents 22:465-478.
10. Brown, K. L., and R. E. Hancock. 2006. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 18:24-30.
11. Chalekson, C. P., M. W. Neumeister, and J. Jaynes. 2002. Improvement in burn wound infection and survival with antimicrobial peptide D2A21 (Demegel). Plast. Reconstr. Surg. 109:1338-1343.
12. Chalekson, C. P., M. W. Neumeister, and J. Jaynes. 2003. Treatment of infected wounds with the antimicrobial peptide D2A21. J. Trauma 54:770-774.
13. Chambers, H. F. 2005. Community-associated MRSA-resistance and virulence converge. N. Engl. J. Med. 352:1485-1487.
14. Cociancich, S., M. Goyffon, F. Bontems, P. Bulet, F. Bouet, A. Menez, and J. Hoffmann. 1993. Purification and characterization of a scorpion defensin, a 4-kDa antibacterial peptide presenting structural similarities with insect defensins and scorpion toxins. Biochem. Biophys. Res. Commun. 194:17-22.
15. Conde, R., F. Z. Zamudio, M. H. Rodriguez, and L. D. Possani. 2000. Scorpine, an anti-malaria and antibacterial agent purified from scorpion venom. FEBS Lett. 471:165-168.
16. Corzo, G., P. Escoubas, E. Villegas, K. J. Barnham, W. He, R. S. Norton, and T. Nakajima. 2001. Characterization of unique amphipathic antimicrobial peptides from venom of the scorpion Pandinus imperator. Biochem. J. 359:35-45.
17. Dai, L., A. Yasuda, H. Naoki, G. Corzo, M. Andriantsiferana, and T. Nakajima. 2001. IsCT, a novel cytotoxic linear peptide from scorpion Opisthacanthus madagascariensis. Biochem. Biophys. Res. Commun. 286:820-825.
18. Ehret-Sabatier, L., D. Loew, M. Goyffon, P. Fehlbaum, J. A. Hoffmann, A. van Dorsselaer, and P. Bulet. 1996. Characterization of novel cysteine-rich antimicrobial peptides from scorpion blood. J. Biol. Chem. 271:29537-29544.
19. Fjell, C. D., R. E. Hancock, and A. Cherkasov. 2007. AMPer: a database and an automated discovery tool for antimicrobial peptides. Bioinformatics 23:1148-1155.
20. Fridkin, S. K., J. C. Hageman, M. Morrison, L. T. Sanza, K. Como-Sabetti, J. A. Jernigan, K. Harriman, L. H. Harrison, R. Lynfield, and M. M. Farley. 2005. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352:1436-1444.
21. Gordon, Y. J., E. G. Romanowski, and A. M. McDermott. 2005. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 30:505-515.
22. Hancock, R. E. 1997. Peptide antibiotics. Lancet 349:418-422.
23. Hancock, R. E., K. L. Brown, and N. Mookherjee. 2006. Host defence peptides from invertebrates: emerging antimicrobial strategies. Immunobiology 211:315-322.
24. Hancock, R. E., and G. Diamond. 2000. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 8:402-410.
25. Hancock, R. E., and R. Lehrer. 1998. Cationic peptides: a new source of antibiotics. Trends Biotechnol. 16:82-88.
26. Jain, R., and L. H. Danziger. 2004. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother. 38:1449-1459.
27. Jenssen, H., P. Hamill, and R. E. Hancock. 2006. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19:491-511.
28. Kennedy, A. D., M. Otto, K. R. Braughton, A. R. Whitney, L. Chen, B. Mathema, J. R. Mediavilla, K. A. Byrne, L. D. Parkins, F. C. Tenover, B. N. Kreiswirth, J. M. Musser, and F. R. DeLeo. 2008. Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc. Natl. Acad. Sci. USA 105:1327-1332.
29. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, and S. K. Fridkin. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
30. Koczulla, A. R., and R. Bals. 2003. Antimicrobial peptides: current status and therapeutic potential. Drugs 63:389-406.
31. Koo, G. C., J. T. Blake, A. Talento, M. Nguyen, S. Lin, A. Sirotina, K. Shah, K. Mulvany, D. Hora, Jr., P. Cunningham, D. L. Wunderler, O. B. McManus, R. Slaughter, R. Bugianesi, J. Felix, M. Garcia, J. Williamson, G. Kaczorowski, N. H. Sigal, M. S. Springer, and W. Feeney. 1997. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J. Immunol. 158:5120-5128.
32. Lamb, H. M., and L. R. Wiseman. 1998. Pexiganan acetate. Drugs 56:1047-1054.
33. Lewis, R. J., and M. L. Garcia. 2003. Therapeutic potential of venom peptides. Nat. Rev. Drug Discov. 2:790-802.
34. Li, J., X. Xu, C. Xu, W. Zhou, K. Zhang, H. Yu, Y. Zhang, Y. Zheng, H. H. Rees, R. Lai, D. Yang, and J. Wu. 2007. Anti-infection peptidomics of amphibian skin. Mol. Cell Proteomics 6:882-894.
35. Lyons, S. A., J. O'Neal, and H. Sontheimer. 2002. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 39:162-173.
36. Marothi, Y. A., H. Agnihotri, and D. Dubey. 2005. Enterococcal resistance-an overview. Indian J. Med. Microbiol. 23:214-219.
37. Martin, E., T. Ganz, and R. I. Lehrer. 1995. Defensins and other endogenous peptide antibiotics of vertebrates. J. Leukoc. Biol. 58:128-136.
38. Miller, L. G., F. Perdreau-Remington, G. Rieg, S. Mehdi, J. Perlroth, A. S. Bayer, A. W. Tang, T. O. Phung, and B. Spellberg. 2005. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352:1445-1453.
39. Moerman, L., S. Bosteels, W. Noppe, J. Willems, E. Clynen, L. Schoofs, K. Thevissen, J. Tytgat, J. Van Eldere, J. Van Der Walt, and F. Verdonck. 2002. Antibacterial and antifungal properties of alpha-helical, cationic peptides in the venom of scorpions from southern Africa. Eur. J. Biochem. 269:4799-4810.
40. Mookherjee, N., and R. E. Hancock. 2007. Cationic host defense peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol. Life Sci. 64:922-933.
41. Moore, A. 2003. The big and small of drug discovery. Biotech versus pharma: advantages and drawbacks in drug development. EMBO Rep. 4:114-117.
42. Mygind, P. H., R. L. Fischer, K. M. Schnorr, M. T. Hansen, C. P. Sonksen, S. Ludvigsen, D. Raventos, S. Buskov, B. Christensen, L. De Maria, O. Taboureau, D. Yaver, S. G. Elvig-Jorgensen, M. V. Sorensen, B. E. Christensen, S. Kjaerulff, N. Frimodt-Moller, R. I. Lehrer, M. Zasloff, and H. H. Kristensen. 2005. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437:975-980.
43. Qiu, X. Q., H. Wang, X. F. Lu, J. Zhang, S. F. Li, G. Cheng, L. Wan, L. Yang, J. Y. Zuo, Y. Q. Zhou, H. Y. Wang, X. Cheng, S. H. Zhang, Z. R. Ou, Z. C. Zhong, J. Q. Cheng, Y. P. Li, and G. Y. Wu. 2003. An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria. Nat. Biotechnol. 21:1480-1485.
44. Shea, K. M. 2003. Antibiotic resistance: what is the impact of agricultural uses of antibiotics on children's health? Pediatrics 112:253-258.
45. Soroceanu, L., Y. Gillespie, M. B. Khazaeli, and H. Sontheimer. 1998. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res. 58:4871-4879.
46. Torres-Larios, A., G. B. Gurrola, F. Z. Zamudio, and L. D. Possani. 2000. Hadrurin, a new antimicrobial peptide from the venom of the scorpion Hadrurus aztecus. Eur. J. Biochem. 267:5023-5031.
47. Trotti, A., A. Garden, P. Warde, P. Symonds, C. Langer, R. Redman, T. F. Pajak, T. R. Fleming, M. Henke, J. Bourhis, D. I. Rosenthal, E. Junor, A. Cmelak, F. Sheehan, J. Pulliam, P. Devitt-Risse, H. Fuchs, M. Chambers, B. O'Sullivan, and K. K. Ang. 2004. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int. J. Radiat Oncol. Biol. Phys 58:674-681.
48. Verhoef, J. 2003. Antibiotic resistance: the pandemic. Adv. Exp. Med. Biol. 531:301-313.
49. Wang, Z., and G. Wang. 2004. APD: the antimicrobial peptide database. Nucleic Acids Res. 32:D590-D592.
50. Yang, D., A. Biragyn, L. W. Kwak, and J. J. Oppenheim. 2002. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 23:291-296.
51. Zasloff, M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395.
52. Zeng, X. C., and S. X. Wang. Evidence that BmTXK beta-BmKCT cDNA from Chinese scorpion Buthus martensii Karsch is an artifact generated in the reverse transcription process. FEBS Lett. 520:183-185.
53. Zeng, X. C., S. X. Wang, Y. Zhu, S. Y. Zhu, and W. X. Li. 2004. Identification and functional characterization of novel scorpion venom peptides with no disulfide bridge from Buthus martensii Karsch. Peptides 25:143-150.